Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients

Completed · Phase 1

Conditions studied: Optic Atrophy, Non-arteritic Anterior Ischemic Optic Neuropathy

In brief

This is an open-label, dose escalation, safety, tolerability and pharmacokinetic study, where active study drug (QPI-1007) will be given to all patients who participate. This study will determine whether QPI-1007 is safe when it is injected into the eye. The study will also reveal if there are any side effects of the drug and how long it takes for the body to clear the drug.

Key facts

Study ID
NCT01064505
Run by
Quark Pharmaceuticals
People needed
48
Starts
2010-02-01
Expected to finish
2013-04-01
Last updated by the study team
2013-05-13

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.